Article Correctness Is Author's Responsibility: Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM

Newswise imageThe inventors of a cancer immunotherapy developed at Roswell Park Comprehensive Cancer Center have announced a major step forward with that therapy, SurVaxM -- a multimillion-dollar licensing deal that will help enable large, randomized clinical trials in both the U.S. and China.